In this issue:
Gefitinib vs erlotinib in advanced NSCLC
KRAS mutations: shorter overall survival
Selumetinib improves survival in KRAS-mutated NSCLC
Pemetrexed-based regimens in ALK+ NSCLC
Bevacizumab + platinum-based regimens in NSCLC
Patients’ views on chemotherapy go
Please login below to download this issue (PDF)